Cargando…

Therapeutic index improvement of antibody-drug conjugates

The commentary by Colombo and Rich recently published in Cancer Cell provides a timely and comprehensive review of the clinical maximum tolerated doses (MTDs) of antibody−drug conjugates (ADCs) and their corresponding small molecules/chemotherapies. The authors identified similarities between their...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gerber, Hans-Peter, Gangwar, Sanjeev, Betts, Alison
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324427/ https://www.ncbi.nlm.nih.gov/pubmed/37408311 http://dx.doi.org/10.1080/19420862.2023.2230618

Ejemplares similares

Development of applicable thiol-linked antibody–drug conjugates with improved stability and therapeutic index
por: Wang, Yanming, et al.
Publicado: (2022)

An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index
por: Hui, Xiwu, et al.
Publicado: (2022)

Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer
por: Webster, Emily M., et al.
Publicado: (2020)

Therapeutic antibodies for infectious diseases
por: Sparrow, Erin, et al.
Publicado: (2017)

Meeting Regulatory Requirements for Drugs with a Narrow Therapeutic Index: Bioequivalence Studies of Generic Once-Daily Tacrolimus
por: Gantar, Kaja, et al.
Publicado: (2020)

Rethinking the INN system for therapeutic antibodies
por: Pottier, Jérémy, et al.
Publicado: (2016)

N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability
por: Ko, Min Ji, et al.
Publicado: (2021)

A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody–Drug Conjugates
por: Verkade, Jorge M. M., et al.
Publicado: (2018)

Construction of paclitaxel-based antibody–drug conjugates with a PEGylated linker to achieve superior therapeutic index
por: Shao, Ting, et al.
Publicado: (2020)

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
por: Oflazoglu, Ezogelin, et al.
Publicado: (2008)

Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19
por: Sempowski, Gregory D., et al.
Publicado: (2020)

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
por: Lu, Guolan, et al.
Publicado: (2020)

Uncovering therapeutic opportunities in the clinical development of antibody‐drug conjugates
por: Nieto‐Jiménez, Cristina, et al.
Publicado: (2023)

Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates
por: Kalim, Muhammad, et al.
Publicado: (2017)

Formalizing drug indications on the road to therapeutic intent
por: Nelson, Stuart J, et al.
Publicado: (2017)

RNA-binding proteins modulate drug sensitivity of cancer cells
por: Rogoyski, Oliver, et al.
Publicado: (2021)

Antibody-based Validation of CNS Ion Channel Drug Targets
por: Rhodes, Kenneth J., et al.
Publicado: (2008)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Engineered therapeutic antibodies with enhanced effector functions: Clinical application of the Potelligent® Technology
por: Matsushita, Takefumi
Publicado: (2011)

Could a revision of the current guidelines for cancer drug use improve the quality of cancer treatment?
por: Lippert, Theodor H, et al.
Publicado: (2014)

Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more
por: Parren, Paul W. H. I., et al.
Publicado: (2017)

Potential of antibody–drug conjugates and novel therapeutics in breast cancer management
por: Lianos, Georgios D, et al.
Publicado: (2014)

Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
por: Kim, Eunhee G., et al.
Publicado: (2015)

Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate
por: Herbener, Peter, et al.
Publicado: (2018)

Therapeutic trials in adult FSGS: lessons learned and the road forward
por: De Vriese, An S., et al.
Publicado: (2021)

Enzymatic glycan remodeling–metal free click (GlycoConnect™) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering
por: Wijdeven, Marloes A., et al.
Publicado: (2022)

An Efficient Conjugation Approach for Coupling Drugs to Native Antibodies via the Pt(II) Linker Lx for Improved Manufacturability of Antibody–Drug Conjugates
por: Merkul, Eugen, et al.
Publicado: (2021)

Approaches to drug therapy for COPD in Russia: a proposed therapeutic algorithm
por: Zykov, Kirill A, et al.
Publicado: (2017)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

Modifications of Antiepileptic Drugs for Improved Tolerability and Efficacy
por: Landmark, Cecilie Johannessen, et al.
Publicado: (2008)

Modulation of Cell State to Improve Drug Therapy
por: Gallo, James M.
Publicado: (2018)

A long story for a short peptide: therapeutic efficacy of a cleavage-specific tau antibody
por: Amadoro, Giuseppina, et al.
Publicado: (2021)

Perspective: The promises of a holistic view of proteins—impact on antibody engineering and drug discovery
por: Phua, Ser-Xian, et al.
Publicado: (2019)

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
por: Smith, L M, et al.
Publicado: (2008)

The European antibody network's practical guide to finding and validating suitable antibodies for research
por: Roncador, Giovanna, et al.
Publicado: (2015)

Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
por: Kalinovsky, Daniel V, et al.
Publicado: (2022)

Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors
por: Anami, Yasuaki, et al.
Publicado: (2022)

The Need for Improved Therapeutic Approaches to Protect the Cornea Against Chemotoxic Injuries
por: McNutt, Patrick M., et al.
Publicado: (2020)

Non-Clinical Models for Neurodegenerative Diseases: Therapeutic Approach and Drug Validation in Animal Models
por: Fernandez, Caridad Ivette, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jka6vlc3hjuq824ice1bkv26u6